Overview
Alistair is an associate in our Seattle Office. His practice includes patent prosecution and portfolio management (domestic and international), competitive landscape analysis, and patentability, infringement, and invalidity investigations. Alistair represents clients ranging from startups to multinational corporations within a variety of technological fields, including biotechnology, medical devices, electronics, and pharmaceuticals.
Alistair received his J.D. from UC Berkeley Law, where he was a member of and contributor to the Berkeley Technology Law Journal and involved with the Samuelson Law, Technology & Public Policy Clinic. Prior to law school, Alistair worked in the biotech industry for three years. Working within R&D groups, Alistair developed molecular assays and assay components at a couple of startups before moving to Illumina, where his work focused on developing tests and setting specifications for use in quality control.
As a former bioengineer, Alistair has the ability to quickly understand new technologies and identify key IP issues.
Alistair joined the firm in 2021.
Education
- University of California - Berkeley (J.D., 2021), Berkeley Technology Law Journal; Samuelson Law, Technology & Public Policy Clinic
- University of California - San Diego (M.S. Bioengineering, 2015), Bioengineering Graduate Society
- University of Minnesota (B.E. Biomedical Engineering, 2013), Cum Laude
News & Insights
Articles
Medical Device Blog
- FDA Accuses Third Party Testing Labs of Falsifying Data
- Test Anxiety: FDA Issues Warning Letters to Test Laboratories
- New Ethylene Oxide Regulations May Raise Cost of Sterilization
- Shutdown Will Impact FDA
- FDA Issues Final Guidance on Transitioning from COVID-19 EUAs
- Cancer Drug Patent Not Dead Yet
- Boston Scientific Acquires Embolization Gel Developer Obsidio, Inc.
Litigation Blog
- A Cure for Written Description and Enablement Headaches: Prior Art
- No Shenanigans: IPRs and Interference Estoppel
- Defining Indefiniteness: When Are Claim Limitations Contradictory?
- Weighty Considerations: Objective Indicia of Non-obviousness
- Collateral Estoppel Is Applicable in IPRs When the Question of Patentability Is the Same
- An ANDA Specification that Directly Addresses Issues of Infringement Controls the Infringement Inquiry
- Sounding Off: Prosecution Disclaimer Requires Unambiguous Intrinsic Evidence
Biotechnology Blog
- FDA Approves First mRNA-Based Flu Vaccine, Highlighting Growing Patent Value in mRNA Platforms
- One Battle After Another: Broad Institute Wins at PTAB in CRISPR Dispute
- Patent Exclusivity and Price Controls: Teva v. Kennedy
- Two Bills Introduced to Target “Patent Thickets” and “Product Hopping”
- CDRH Announces Pilot Program to Improve Recall Communication
- Science Group Sues FDA Over New Laboratory-Developed Test Rule
- FDA Issues Final Rule on Laboratory-Developed Tests
- FDA Approves Generic Fluorescein Injection
- Supreme Court Issues Stay in Mifepristone Case, Preserving Status Quo for Now
